Skip directly to content

Safety Information

ARICEPT®(donepezil hydrochloride)

Indications and Clinical Use:

ARICEPT is indicated for symptomatic treatment of patients with mild, moderate and severe dementia of the Alzheimer’s type (AD).


Patients with hypersensitivity to piperidine derivatives.

Relevant warnings and precautions:

  • Cholinesterase inhibitors (ChEIs) may have vagotonic effects on heart rate
  • Increased risk of seizures
  • Increases gastric acid secretion, nausea, diarrhea and vomiting
  • As with ChEIs, caution with anesthesia
  • Caution with asthma, COPD, low body weight (≥85 years) and elderly patients with comorbid disease
  • Close monitoring in patients with hepatic and renal disease
  • Not recommended for use in children

For more information:

Please consult the product monograph by clicking here for important information relating to adverse reactions, drug interactions, and dosing information.

ARICEPT ® Eisai Co. Ltd., owner/Pfizer Canada Inc., Licensee